Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
1.640
+0.010 (0.61%)
At close: Dec 5, 2025, 4:00 PM EST
1.660
+0.020 (1.22%)
After-hours: Dec 5, 2025, 4:32 PM EST
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $493.10K in the quarter ending September 30, 2025, a decrease of -85.58%. This brings the company's revenue in the last twelve months to $4.49M, up 1.51% year-over-year. In the year 2024, Ensysce Biosciences had annual revenue of $5.21M with 133.58% growth.
Revenue (ttm)
$4.49M
Revenue Growth
+1.51%
P/S Ratio
0.70
Revenue / Employee
$560,997
Employees
8
Market Cap
5.81M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ENSC News
- 3 days ago - Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Accesswire
- 15 days ago - Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - Accesswire
- 18 days ago - Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs - Accesswire
- 21 days ago - Ensysce Biosciences Reports Third Quarter 2025 Financial Results - Accesswire
- 2 months ago - Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 - Accesswire
- 3 months ago - Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium - Accesswire
- 3 months ago - Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025 - Accesswire
- 4 months ago - Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - GlobeNewsWire